FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting FDA mulls compounding for peptides previously flagged over safety risks BioSpace When will the FDA reclassify BPC 157 to Category 1 Octagon AI FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of